Meyer Andrew Hollman 4
4 · Janux Therapeutics, Inc. · Filed Nov 14, 2025
Insider Transaction Report
Form 4
Meyer Andrew Hollman
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-14$10.59/sh+3,333$35,296→ 88,307 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-14−3,333→ 118,101 totalExercise: $10.59Exp: 2031-05-13→ Common Stock (3,333 underlying) - Sale
Common Stock
2025-11-14$30.00/sh−3,333$99,990→ 84,974 total
Footnotes (3)
- [F1]Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2024 and 2,834 shares acquired under the Plan on May 15, 2025.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
- [F3]Immediately exercisable.